Is it feasible to measure Nephrocheck in patients with AKI stage 1?
Research type
Research Study
Full title
Is it feasible to measure a urinary biomarker (Nephrocheck) in patients with AKI stage 1?
IRAS ID
236746
Contact name
Nicholas Selby
Contact email
Sponsor organisation
Royal Derby Hospital
Duration of Study in the UK
0 years, 9 months, 2 days
Research summary
The onset of AKI is often difficult to identify unless a clear cause is evident. Cr is frequently used to assess kidney
function but the rise in Cr becomes evident when the kidney function has already declined. Earlier detection of AKI
through novel biomarkers could allow timely changes in patient management
NephroCheck3 is a urine test that detects two biomarkers:
• Insulin-like Growth Factor Binding Protein 7 (IGFBP-7)
• Tissue Inhibitor of Metalloproteinase 2 (TIMP-2).
Nephrocheck has been studied in patients with AKI in ICU setting and following cardiac surgery. In these settings, it is
easy to use Nephrocheck as the patients are all catheterised and collection of urine samples is therefore easy.
Tthe purpose of this study is to determine whether performing a urinary biomarker is feasible in patients with AKI
stage 1 within 12 hours of admissions in a general medical assessment unit (MAU), where the majority of patients will
not have a urinary catheterREC name
Wales REC 7
REC reference
18/WA/0081
Date of REC Opinion
21 Mar 2018
REC opinion
Further Information Favourable Opinion